Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 May;49(10):1301-1313.
doi: 10.1111/apt.15227. Epub 2019 Mar 20.

Mucosal 5-aminosalicylic acid concentration, drug formulation and mucosal microbiome in patients with quiescent ulcerative colitis

Maya Olaisen  1   2 , Olav Spigset  1   3 , Arnar Flatberg  1 , Atle van Beelen Granlund  1   4 , Wenche Rødseth Brede  3 , Grethe Albrektsen  5 , Elin Synnøve Røyset  1   6 , Bodil Gilde  7 , Arne Kristian Sandvik  2   4 , Tom Christian Martinsen  1   2 , Reidar Fossmark  1   2
Affiliations

Mucosal 5-aminosalicylic acid concentration, drug formulation and mucosal microbiome in patients with quiescent ulcerative colitis

Maya Olaisen et al. Aliment Pharmacol Ther. 2019 May.

Abstract

Background: 5-aminosalicylic acid (5-ASA) is the first-line therapy for ulcerative colitis (UC). 5-ASA acts locally in the colonic mucosa by numerous proposed mechanisms, and is metabolised by N-acetyltransferase (NAT). Large variations in mucosal 5-ASA concentrations have been reported, but the underlying mechanisms are not understood.

Aim: To study the relationship between 5-ASA concentration, 5-ASA formulation, NAT genotype and bacterial microbiome in patients with UC.

Methods: Patients with quiescent UC, using monotherapy of Mezavant (n = 18), Asacol (n = 14) or Pentasa (n = 10), 4.0-4.8 g/day were included. 5-ASA was measured in colonic mucosal biopsies and serum by ultra-high performance liquid chromatography. NAT genotypes were determined by Sanger sequencing. Bacterial microbiome was sequenced from faeces and mucosa by 16S rRNA sequencing using Illumina Miseq.

Results: Mezavant provided the highest mucosal 5-ASA levels (geometric mean 2.39 ng/mg), followed by Asacol (1.60 ng/mg, 33% lower, P = 0.50) and Pentasa (0.57 ng/mg, 76% lower, P = 0.033). Mucosal 5-ASA concentration was not associated with NAT genotype, but serum 5-ASA concentration and NAT1 genotype was associated (P = 0.044). Mucosal 5-ASA concentration was positively associated with mucosal bacterial diversity (P = 0.0005) and bacterial composition. High mucosal 5-ASA concentration was related to reduced abundance of pathogenic bacteria such as Proteobacteria, and increased abundance of several favourable bacteria such as Faecalibacterium.

Conclusions: Mucosal 5-ASA concentration is positively associated with bacterial diversity and a mucosal bacterial composition that are perceived favourable in UC. Mezavant yielded higher mucosal 5-ASA concentrations than Pentasa. 5-ASA may have beneficial effects on the mucosal microbiome, and high concentrations possibly amend dysbiosis in UC.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Mucosal 5‐aminosalicylic acid (5‐ASA) concentration in five colonic biopsies sampled 40, 25 and 10 cm from the anal verge in patients with ulcerative colitis using three different oral 5‐ASA formulations. Each line represents one patient
Figure 2
Figure 2
Bacterial diversity analysis in biopsies and faecal samples in patients with ulcerative colitis using 5‐aminosalicylic (5‐ASA). Red line = regression line, dark grey area = 95% confidence interval
Figure 3
Figure 3
Bacterial phyla correlated to 5‐aminosalicylic acid (5‐ASA) mucosal concentration in biopsies and faecal samples in patients with ulcerative colitis (UC). P: phylum, P = adjusted P‐value, B = regression coefficient, Rlog = regularised logarithm transformation. Blue line = regression line. Dark grey area = 95% confidence interval
Figure 4
Figure 4
Selected bacterial families, genera and species significantly correlated to 5‐aminosalicylic acid (5‐ASA) mucosal concentration in mucosal biopsies in patients with ulcerative colitis; (A) Lachnospiraceae, (B) Ruminococcaceae, (C) Faecalibacterium, (D) Blautia, (E) Faecalibacterium prausnitzii, (F) Cloacibacterium (for complete list see Figures S5‐S7). P, phylum; C, class; F, family; G, genus; Sp, species. P = adjusted P‐value; B = regression coefficient, Rlog = regularised logarithm transformation. Blue line = regression line. Dark grey area = 95% confidence interval
See this image and copyright information in PMC

Comment in

References

    1. Wang Y, Parker CE, Bhanji T, Feagan BG, MacDonald JK. Oral 5‐aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2016;4:CD000543. - PMC - PubMed
    1. Wang Y, Parker CE, Feagan BG, MacDonald JK. Oral 5‐aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2016;5:CD000544. - PMC - PubMed
    1. Lichtenstein GR, Kamm MA. Review article: 5‐aminosalicylate formulations for the treatment of ulcerative colitis–methods of comparing release rates and delivery of 5‐aminosalicylate to the colonic mucosa. Aliment Pharmacol Ther. 2008;28:663‐673. - PubMed
    1. D'Inca R, Paccagnella M, Cardin R, et al. 5‐ASA colonic mucosal concentrations resulting from different pharmaceutical formulations in ulcerative colitis. World J Gastroenterol. 2013;19:5665‐5670. - PMC - PubMed
    1. D'haens G, Hommes D, Engels L, et al. Once daily MMX mesalazine for the treatment of mild‐to‐moderate ulcerative colitis: a phase II, dose‐ranging study. Aliment Pharmacol Ther. 2006;24:1087‐1097. - PubMed

Publication types

MeSH terms